Disparities in the diagnostic process of Duchenne and Becker muscular dystrophy
- PMID: 21836521
- DOI: 10.1097/GIM.0b013e31822623f1
Disparities in the diagnostic process of Duchenne and Becker muscular dystrophy
Abstract
Purpose: To determine whether sociodemographic factors are associated with delays at specific steps in the diagnostic process of Duchenne and Becker muscular dystrophy.
Methods: We examined abstracted medical records for 540 males from population-based surveillance sites in Arizona, Colorado, Georgia, Iowa, and western New York. We used linear regressions to model the association of three sociodemographic characteristics with age at initial medical evaluation, first creatine kinase measurement, and earliest DNA analysis while controlling for changes in the diagnostic process over time. The analytical dataset included 375 males with information on family history of Duchenne and Becker muscular dystrophy, neighborhood poverty levels, and race/ethnicity.
Results: Black and Hispanic race/ethnicity predicted older ages at initial evaluation, creatine kinase measurement, and DNA testing (P < 0.05). A positive family history of Duchenne and Becker muscular dystrophy predicted younger ages at initial evaluation, creatine kinase measurement and DNA testing (P < 0.001). Higher neighborhood poverty was associated with earlier ages of evaluation (P < 0.05).
Conclusions: Racial and ethnic disparities in the diagnostic process for Duchenne and Becker muscular dystrophy are evident even after adjustment for family history of Duchenne and Becker muscular dystrophy and changes in the diagnostic process over time. Black and Hispanic children are initially evaluated at older ages than white children, and the gap widens at later steps in the diagnostic process.
Similar articles
-
Racial and Ethnic Differences in Timing of Diagnosis and Clinical Services Received in Duchenne Muscular Dystrophy.Neuroepidemiology. 2023;57(2):90-99. doi: 10.1159/000528962. Epub 2023 Jan 9. Neuroepidemiology. 2023. PMID: 36623491 Free PMC article.
-
Risk Factors for First Fractures Among Males With Duchenne or Becker Muscular Dystrophy.J Pediatr Orthop. 2015 Sep;35(6):640-4. doi: 10.1097/BPO.0000000000000348. J Pediatr Orthop. 2015. PMID: 25379822
-
Muscular Dystrophy Surveillance Tracking and Research Network (MD STARnet): case definition in surveillance for childhood-onset Duchenne/Becker muscular dystrophy.J Child Neurol. 2010 Sep;25(9):1098-102. doi: 10.1177/0883073810371001. J Child Neurol. 2010. PMID: 20817884 Free PMC article.
-
Genetics and emerging treatments for Duchenne and Becker muscular dystrophy.Pediatr Clin North Am. 2015 Jun;62(3):723-42. doi: 10.1016/j.pcl.2015.03.008. Epub 2015 Apr 20. Pediatr Clin North Am. 2015. PMID: 26022172 Review.
-
Identifying Non-Duchenne Muscular Dystrophy-Positive and False Negative Results in Prior Duchenne Muscular Dystrophy Newborn Screening Programs: A Review.JAMA Neurol. 2016 Jan;73(1):111-6. doi: 10.1001/jamaneurol.2015.3537. JAMA Neurol. 2016. PMID: 26594870 Review.
Cited by
-
Recent Advances in Pre-Clinical Development of Adiponectin Receptor Agonist Therapies for Duchenne Muscular Dystrophy.Biomedicines. 2024 Jun 25;12(7):1407. doi: 10.3390/biomedicines12071407. Biomedicines. 2024. PMID: 39061981 Free PMC article. Review.
-
Subspecialty Health Care Utilization in Pediatric Patients With Muscular Dystrophy in the United States.Neurol Clin Pract. 2024 Aug;14(4):e200312. doi: 10.1212/CPJ.0000000000200312. Epub 2024 May 31. Neurol Clin Pract. 2024. PMID: 38855715
-
Draft Guidance for Industry Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, and Related Dystrophinopathies - Developing Potential Treatments for the Entire Spectrum of Disease.J Neuromuscul Dis. 2024;11(2):499-523. doi: 10.3233/JND-230219. J Neuromuscul Dis. 2024. PMID: 38363616 Free PMC article.
-
The Early Care (0-3 Years) In Duchenne Muscular Dystrophy Meeting Report.J Neuromuscul Dis. 2024;11(2):525-533. doi: 10.3233/JND-230180. J Neuromuscul Dis. 2024. PMID: 38189762 Free PMC article.
-
Disease progression modeling of the North Star Ambulatory Assessment for Duchenne Muscular Dystrophy.CPT Pharmacometrics Syst Pharmacol. 2023 Mar;12(3):375-386. doi: 10.1002/psp4.12921. Epub 2023 Feb 14. CPT Pharmacometrics Syst Pharmacol. 2023. PMID: 36718719 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous

